Nestle has launched in China its first growing up formula containing human milk oligosaccharides (HMOs), namely 2'-fucosyllactose (2'FL) and lacto-N-(neo)tetraose (LNnT).
Nestlé has launched a new proprietary blend for infant nutrition combining a probiotic strain with varying levels of six human milk oligosaccharides (HMOs) to support the developing infant through its life stages.
In a new systematic review, Chr. Hansen scientists have compiled data from 26 clinical studies on HMOs, concluding there is a wealth of evidence that these are well-tolerated modulators of the gut microbiome providing health benefits.
Adam Baker, director of science at Chr. Hansen, discussed recent in-house clinical trials observing an amplified response following administration of probiotics with HMOs, compared with pre- or probiotics given alone, at Probiota last week.
A systematic review of dozens of studies has revealed that levels of the five most prevalent HMOs in breast milk vary widely, and infant formula development should accommodate this variability.
A recent analysis has found that the global infant formula ingredients market is expanding steadily with the rising middle class and the demand for high-quality infant formula gains traction.
